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Abstract
Conducting clinical trials in developing countries often presents significant ethical, organisational, cultural and
infrastructural challenges to researchers, pharmaceutical companies, sponsors and regulatory bodies. Globally, these
regions are under-represented in research, yet this population stands to gain more from research in these settings
as the burdens on health are greater than those in developed resourceful countries. However, developing
countries also offer an attractive setting for clinical trials because they often have larger treatment naive
populations with higher incidence rates of disease and more advanced stages. These factors can present a
reduction in costs and time required to recruit patients. So, balance needs to be found where research can be
encouraged and supported in order to bring maximum public health benefits to these communities. The
difficulties with such trials arise from problems with obtaining valid informed consent, ethical compensation
mechanisms for extremely poor populations, poor health infrastructure and considerable socio-economic and
cultural divides. Ethical concerns with trials in developing countries have received attention, even though many
other non-ethical issues may arise. Local investigator initiated trials also face a variety of difficulties that have not
been adequately reported in literature. This paper uses the example of the Cameroon Mobile Phone SMS trial to
describe in detail, the specific difficulties encountered in an investigator-initiated trial in a developing country. It
highlights administrative, ethical, financial and staff related issues, proposes solutions and gives a list of additional
documentation to ease the organisational process.
Introduction
Randomized clinical trials are the cornerstone of
evidence-based decision making and are considered the
‘Gold Standard’ for clinical research. In recent years a
huge scientific revolution towards evidence-informed
health care decision-making has boosted the clinical
trial industry [1]. The recognition of systematic reviews
(which mostly use randomized trials as units of analysis)
as important tools in health care decision making has
also given a silent nod towards the growth of the indus-
try. The Cochrane collaboration is one of the largest
producers of systematic reviews [2].
Even though the clinical trial industry is growing, a
simple search by location on the clinical trials website,
clinicaltrials.gov [3] will reveal 24 trials in Cameroon as
opposed to 7662 in Canada or 50896 in the United
States of America (USA). On the World Health Organi-
zation (WHO) International Clinical Trials registry Plat-
form (ICTRP), the numbers are similar [4]. These
differences reflect the differences in experience in all the
parties involved; regulatory bodies, researchers and par-
ticipants. Additional differences arise from culture,
health infrastructure and socioeconomic divides [5]. In
low-resource settings, structures such as the Data Safety
and Monitoring Board (DSMB), Community Advisory
Boards (CAB), Regulatory Authorities (RA) and
Institutional Review Boards (IRB) that play key roles in
monitoring and approval of trials may be non-existent,
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non- functional or lack the skills to critically appraise a
research protocol. In Cameroon the National Ethics
Committee (NEC) plays all these roles. In consequence,
trial capacity is lacking, and research centres in low
resource settings are unable to lead large scale indepen-
dent research projects [6].
For the purposes of accrued external validity, low costs,
faster recruitment and in some cases, reduced set-up
times, commercial clinical trials are increasingly being
conducted in middle income countries like China and
India [5]. It is estimated that a trial in China or India
could cost somewhere between a third to half of what it
would cost in the United States. Also, the incidence rates
of some diseases may be too low for a large scale trial in
a developed country [7]. Commercial (for-profit) research
initiatives will understandably aim for the least costly set-
tings, and will invest primarily in drugs and technologies,
as they need to make profits. Whilst there is of course a
need for a robust supply chain of new drugs and vaccines
for all settings, we also need to support research that
helps improve the way we use existing therapies and
manage illnesses. These disease management trials bene-
fit the local populations and respond to the countries’
priorities [5]. They are highly effective mechanisms for
bringing about improvements in disease outcomes.
Examples include finding new uses for antibiotics, or
evaluating how to improve nurse training.
There are relatively few commercial trials in develop-
ing countries and a lack of suitably trained and
resourced centres to conduct non-commercial research.
Therefore the situation is that little research is per-
formed in the low income countries with the highest
disease burden.
The ideal solution for this research dilemma would be
for local investigators to lead the initiation and conduct
of nationally relevant trials, as they will be more in tune
with the socio-cultural context, the disease burden,
national priorities and infrastructural challenges.
The literature on the conduct of clinical trials in low
resource settings mostly covers ethical issues, and the
need to avoid double standards or the difficulties in
obtaining meaningful informed consent in places were
community consent applies. They address post-trial
access to care and compensatory mechanisms with
particular reference to middle-income Asian countries
such as India and China [8-12]There is a lack of data on
trial methods and operational challenges in low- income
countries globally. There is a need for researchers based
in developing countries to work together and share their
experiences, methods and resources. There are some
initiatives beginning to meet this need [6,13], and here
we provide some of our experiences.
The main aim of this paper is to discuss the issues
surrounding the conduct of the Cameroon Mobile
Phone SMS (CAMPS) trial [14], an investigator-initiated
and designed trial in a low-resource setting. We do not
intend to be critical of any health system or administra-
tive procedures in low resource setting countries, rather
we hope to share our experiences from the CAMPS trial
to shed light on key challenges that researchers may
encounter in similar settings and how to address them.
Some of the issues raised may also apply to multi-centre
trials with some sites in low resource settings, adding to
the relevance of sharing research experiences with
researchers worldwide.
Here we describe the CAMPS trial in the context of
its setting, discuss the administrative, ethical and finan-
cial issues related to the CAMPS trial and how the
human resources were managed. We also provide a list
of documents which can improve the management of a
trial and the quality of the data collected. We have
made these documents available for others to use on the




CAMPS is an investigator-initiated, randomized con-
trolled trial of motivational mobile phone text messages
versus routine care to improve adherence to Anti-Retro-
viral Therapy (ART) among people living with Human
Immune Deficiency Virus (HIV) over 6 months. It is a
single-blinded trial involving 198 participants divided
into two groups. Participants were randomized to
receive either the intervention (weekly motivational
mobile phone text messages and usual care) or usual
care alone. The CAMPS trial [14] is the first mobile
phone technology trial in Cameroon. It is also the first
registered trial in the country on technological aids to
adherence for ART, which we present as a pragmatic
example of a locally-led disease management trial.
Study setting
Situated in West Africa, Cameroon is a resource stricken
country with an adult HIV prevalence of 5.1% [15]. The
unique study site, the Yaoundé Central Hospital (YCH)
Accredited Treatment Centre (ATC) has been used for
observational studies, but hardly for clinical trials. It is
located in the capital city, Yaoundé. The YCH is a referral
hospital with a staff of about 800, including 95 doctors
[16]. The ACT provides care for more than 6500 people
living with HIV.
Ethical approval and Administrative issues
Ethical approval
The application for ethical clearance was straight-forward,
as the National Ethics Committee (NEC) already had a
list of requirements to be submitted with the application.
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The list can be sent by email upon request. A document
processing fee must be paid based on the source of the
funding.
However, owing to the fact that Cameroon is a bilin-
gual country, some documents, notably the consent
form, information booklet, data collection form and
investigator brochure had to be submitted in both lan-
guages. Using only English and French is far cheaper,
than having to translate into all the local languages.
Cameroon has 286 local languages[17].
Second, the NEC was unfamiliar with certain standar-
dized reporting tools, namely the Consolidated
Standards for Reporting Trials (CONSORT) flow dia-
gram [18] and requested that it be removed from the
protocol. Review was completed within a month.
Finally, we were clarified on the legal age of consent
in Cameroon, which is 21 years as opposed to 18 years
in many other countries, thus redefining our concept of
‘children’ and modifying our inclusion criteria.
Many papers have identified the ethical challenges of
running a trial in a developing country and the need for
protecting the developing countries participating in
international clinical trials [5,9-11,19]. With drug trials,
adverse effects are the main risk involved and can
usually be identified directly, sometimes as secondary
outcomes. How do you define the risk of receiving a
text message? We identified one concern and that was
the possibility of disclosure of privacy and potential dis-
closure of HIV status. Our trial was designed to protect
privacy and data. However, we needed to plan for acci-
dental disclosure. If this happened, how could this be
managed and what appropriate compensation should be
offered? This issue is context specific, especially in a
country where there is still some lingering stigma
associated with HIV [20]. In other similar trials, loss of
privacy was not a deterrent to the intervention [21]. Such
implementation difficulties may be encountered fre-
quently, especially since the International Conference on
Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use - Good Clinical
Practice (ICH-GCP) guidelines[22] offer little guidance
for non-drug, non-industry interventions [6,23,24].
Post trial access to care was a challenge and this is a
difficult area for many groups planning research in set-
tings such as ours. We discussed this carefully and con-
cluded that it could not be guaranteed without ensuring
that the intervention was effective, not unreasonably
expensive, could be performed on a large scale and that
there was a legal framework established with the mobile
operators to ensure anonymity of the participants.
Administrative issues
Administrative bottle necks can seriously impede the
ability of researchers to set up studies, so much so that
delays can make the trial meaningless or out of date by
the time the study is allowed to start. This is a serious
issue and so it is unfortunate that these aspects are
often overlooked in discussions around what impedes
research. These governance and organisational aspects
are fundamentally important, yet it is difficult to obtain
funding, training and support in this area for trial staff.
Each modification in the protocol, say for example
adding one more interviewer, required a change in the
budget. These changes, no matter how slight were diffi-
cult to run through administration.
The finances provided for the running of the trial had
to pass through the normal financial procedures of YCH
and the Centre for the Development of Best Practices in
Health (CDBPH). The later is a research-dedicated body
while the former is not, however the former (YCH)
being hierarchically superior to the latter is responsible
for the approval of all purchases and expenditures, and
has the right to reject expenses they deem unnecessary.
This left little room for modification of the budget,
despite the constant need to adapt the protocol due to
scientific counsel, ethical recommendations and miscel-
laneous needs. A second difficulty was the fact that the
finances were disbursed in two bi-annual instalments.
The YCH required us to submit a complete budget, but
within the limits of the account balance. In other words
we were not allowed to budget beyond what we had at
hand. We found ourselves juggling two budgets, one
covering the first instalment and the other covering
their entire sum allocated for the project.
Financial issues
Cost of running a trial
Compared to developed countries, the cost of running a
trial is significantly cheaper in developing countries.
There are many reasons for this, including lower salary
and overhead costs and that less time is required to
enrol participants [5,7]. The compensatory mechanisms
used in this trial, which represent a considerable portion
of the budget, are addressed in detail below.
Participant compensation
As can be expected, the NEC and the trial research
group did not agree with financial compensation for
participants. The main reasons advanced were that this
practice would hamper future research with less fund-
ing, may induce participants into trying to satisfy the
researchers and also causes patients to come for
unscheduled visits if they will get some transport
money. The NEC suggested that we need not specify in
the information booklet that there was no financial
compensation. We gave them preferential treatment by
reducing their waiting times before they could see their
doctors. This seemed to be the most acceptable and
fairest method of compensation as we were helping
them to regain time lost during the interviews.
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Interviewer compensation
Interviewer salaries were open to more discussion. Some
of them had experience with data collection and felt
they should be compensated per filled questionnaire.
The interviewers and the principal investigator agreed
that the workload would be evaluated during the testing
of the questionnaire. Bearing in mind the workload
involved, the distraction from their regular duties, the
need above all for quality data, from motivated inter-
viewers and the difficulty in finding people interested in
research we considered a higher financial compensation
level. On the other hand, we could not provide compen-
sations which would compete with their usual salaries,
as this could be a disincentive to work. We were also
limited by budget constraints. Lastly their compensation
would also depend on the modalities involved in pay-
ment. It was initially unclear whether to pay them per
questionnaire filled (would we consider a questionnaire
to be baseline data for one patient, or a complete set of
baseline, interim and final data?), per month (there were
some months during which the interviewers had no
planned activities) or a lump sum per data collection
period (a salary for baseline, interim and final data col-
lection). We finally decided to pay them lump sums per
data collection period, provide communication airtime,
and to establish contracts stipulating the number of
patients to be enrolled and undisclosed bonuses for
promptness and collection of high quality data. Despite
this apparently attractive compensation scheme, their
salary criterion (fifty patients enrolled per interviewer)
was similar to the compensation for recruiting one
patient into a foreign sponsored multi-centre trial [25].
A top-up salary payment for staff working in trials in
developing countries is a challenging issue for research-
ers seeking to set up independent trials in these regions.
On one hand it is quite understandable that healthcare
workers on relatively low salaries should be compen-
sated for carrying tasks beyond their normal roles.
However these costs for trials can add up and make
them prohibitively expensive. This area needs some
discussion between institutions where research is con-
ducted and ministries of health, as a solution could
encourage more locally run research that benefits local
public health goals.
Team of investigators and study staff issues
Our project staff comprised a principal investigator (PI),
a study site coordinator (SSC), a supervisor and a
research group made up of public health physicians,
specialists in research synthesis, anthropologists and
health economists. We had substantial support from
renowned clinical trial experts and a biostatistician from
the McMaster University in Canada. We found that an
administrative officer was a critical component of the
team. He was responsible for ensuring that all
documents were translated and submitted on time, orga-
nized meetings and trainings for interviewers, drafted all
the legal and administrative documents (applications to
the YCH and NEC, contracts with interviewers, disbur-
sement of funds, and provision of equipment) managed
the budget, and archived all trial related activities. It is
critical to mention here that there is a special need for
administrative letters to have the right formatting and
content without which simple processes can be delayed
for months. We also sought guidance, advice and
resources from the Global Health Trials website. This
platform has created a community of clinical researchers
from developing countries who support research
through sharing experience and resources.
In a resource constrained setting, human resources
(including highly qualified research personnel) are just
one of the limited resources. Drawing interviewers from
the already limited pool of health workers is the only way
to get staff that have some knowledge on the content of
the research, are familiar with patient communication
and may benefit from the results of well conducted
research. Despite a previous training session, our inter-
viewers had difficulties with filling the questionnaire and
required repeated explanations on the concept and
importance of research techniques like randomization
and blinding, and tools like the visual analogue scale.
Table 1 summarises the difficulties that may be encoun-
tered when organising a trial in a low resource setting
and possible ways to address the issues.
Additional documentation
Each review body typically provides a list of documents
required to accompany an application for ethical
approval. Table 2 is list of other useful documents that
may ease the research process. These additional logs
and registers permitted us to collect additional and rele-
vant data that could not be put in the questionnaire,
ensure quality control, provide timely feedback to inter-
viewers and also to reduce losses to follow up. These
documents complement the ICH-GCP list of essential
documents [22], and we have placed them on the Global
Health Trials website.
Trial registration is another important component of
the trial process. Registering trials in international
registries ensures that the data is made available to the
public and limits the possibility of publication bias and
selective reporting. It enhances decision making and
prevents duplication of efforts. The revised Declaration
of Helsinki emphasizes that all clinical trials must be
registered in a public data base even before the recruit-
ment of the first subject [26]. This again can be challen-
ging for independent researchers as the process has to
be completed by a sponsor. It is often a problem to
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identify which of the organisations involved can and will
act as a sponsor. The sponsor is required to provide
trial indemnity insurance.
Finally, trialists are recommended to use uniform
reporting criteria like the CONSORT statement to
ensure that trial protocols adhere to high design and
methodological standards [18,27].
Current initiatives
Support structures for clinical trials exist in the USA,
United Kingdom (UK), Canada and other developed
countries. They assist non-commercial trialists, and pro-
vide guidance to ensure that their trials are legal and
compliant. They also make the regulations more straight-
forward and less daunting [6]. Capacity-building in clini-
cal trials is still needed in most developing countries. The
creation of clinical trial sites in low resource settings
based on national research needs and the availability of
competent or potentially trainable staff can improve the
research culture and promote centres of excellence from
which other local researchers can copy good practices.
The African Malaria Network Trust (AMANET) and the
Gates Malaria Partnership (GMP) are good examples of
how capacity strengthening can promote high quality
research [28,29]. Partnerships with the high income
countries like the European and Developing Countries
Clinical Trials Partnership (EDCTP) that promote inves-
tigator driven research and concentrate on the major
killer diseases, while supporting regulatory and ethics
activities may be the way forward [30]. The Global Health
Clinical Trials platform is beginning to meet this gap by
providing an online professional network for clinical tri-
alists. The network provides a good discussion forum for
research staff in resource-limited settings to share their
problems and exchange ideas for solutions [13].
Conclusions and recommendations
Investigator-initiated trials may face similar difficulties
with trials sponsored by international bodies. These dif-
ficulties will be related to handling the regulatory
bodies, administrative and financial bottlenecks, multiple
languages, patient compensation options, interviewer
compensation modalities, and additional documents
required to ease the collection of data.
Table 1 List of difficulties that may be encountered and potential solutions
Difficulties that may be
encountered
Potential solutions
Regulatory bodies with different
standards
Loco- regional recognition of international standards
Adaptation of international standards to local realities
Administrative bottle necks Creation of research managing bodies within the administration
Financial bottle necks Budgets should be drawn after extensive ground work
Multiple languages The local languages should be considered from the conception stages
Patient compensation options Ethical, feasible options should be employed after consulting with patient associations, other researchers and
health personnel
Interviewer compensation modalities All the options should be discussed openly with the interviewers during the preliminary stages and contracts
established
Inadequate interviewer competence Training and capacity building
Different ages for legal consent Country specific age of legal consent must be taken into account when drafting the protocol
No dedicated administrative officer An experienced administrative officer should be hired




Names of interviewer, duration of recruitment period, roles and responsibilities of
the investigators and interviewers including number of participants to be enrolled
Clearly defines roles and responsibilities of




Dates, number of forms filled, interviewer names, problems encountered, refusals
and non-eligible subjects
Easily exploitable enrolment data, quality
control of data, a good feedback mechanism
Trial contact
list
Names, functions and phone numbers of everybody involved in the trial Handy contact list, permits real time




Names of participants, dates of enrolment, date of next visit Essential for interviewers to track patients
and prepare for follow-up visits
Participant
feedback log
Dates, times, contact addresses and content of feedback from participants Provides ongoing monitoring of intervention
Useful data for providing a context for later
findings
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Based on the current literature and our experience
with the CAMPS trial, we recommend training and
capacity building for regulatory authorities.
Additionally, independent support networks for clini-
cal trials are necessary to ensure that specific challenges
are addressed, tools are provided and protocols are
respected.
Delays due to financial and administrative hurdles can
be sorted out by channelling funds directly to the point
of expenditure. Inclusion of local investigators at the
conception and design stages of a trial may help to
reduce the likelihood of unforeseen expenditures. Finan-
cial audits can also help to safeguard accountability, but
should not be an impediment to the research process.
Possible language barriers need to be taken into
account as part of the planning. Such plans would need
to include the testing and verification of translations for
accuracy.
Preparedness and adaptability are essential ingredients
for successful conduct of clinical trials in any setting,
especially resource poor settings. Having an administra-
tive officer dedicated to handling administrative issues
related to the trial can be an invaluable asset. This
would also allow the scientist to devote more time to
the scientific aspects of the trial. This requirement is
necessary when the administrative requirements may
represent a substantial hindrance to the progress of the
trial.
Multisite trials should have national coordinators
selected before the onset of the trial who will participate
in the conception of the trial. Investigator-initiated prag-
matic trials are arguably the way forward for clinical
research in developing countries[31]. Local participants
can play an important role in planning trials to ensure
that protocols are culturally sensitive and beneficial [32].
Trials should also target the specific medical needs of
the country as perceived by the country [33]. It is
equally important that the profession of Clinical Trial
Scientist be recognized as a viable career path for
researchers in developing countries [6].
List of abbreviations
ACT: Accredited Treatment Centre; AMANET: African Malaria Network Trust;
ART: Anti-Retroviral Therapy; CAB: Community Advisory Boards; CAMPS:
Cameroon Mobile Phone SMS; CIHR: Canadian Institutes of Health Research;
CONSORT: Consolidated Standards for Reporting Trials; CDBPH: Centre for
the Development of Best Practices in Health; CTN: Canadian HIV Trials
Network; DSMB: Data and Safety Monitoring Boards; EDCTP: European and
Developing Countries Clinical Trials Partnership; GCP: Good Clinical Practice;
GMP: Gates Malaria Partnership; HIV: Human Immunodeficiency Virus; ICH:
International Conference of Harmonisation; ICTRP: International Clinical Trials
Registry Platform; IRB: Institutional Review Board; NEC: National Ethics
Committee; PI: Principal Investigator; RA: Regulatory Authorities; SSC: Study
Site Coordinator; UK: United Kingdom; USA: United States of America; WHO:
World Health Organisation; YCH: Yaoundé Central Hospital.
Acknowledgements
This paper is supported in part by the Canadian Institutes of Health Research
(CIHR) HIV Clinical Trials Network (CTN) in the form of an international
postdoctoral research fellowship awarded to the first author. Dr Thabane is a
clinical trials mentor for CIHR under the RCT Mentorship Programme.
Author details
1Centre for the Development of Best Practices in Health (CDBPH), Yaoundé
Central Hospital, Henri Dunant Avenue, Messa, PO Box 87, Yaoundé,
Cameroon. 2Department of Clinical Epidemiology and Biostatistics, McMaster
University, Hamilton, ON, Canada. 3Biostatistics Unit, Father Sean O’Sullivan
Research Centre, St Joseph’s Healthcare, Hamilton, ON, Canada. 4Global
Health Clinical Trials Programme, Centre for Vaccinology and Tropical
Medicine, University of Oxford, Churchill Hospital, UK.
Authors’ contributions
LM conceived of the paper. LT, POZ and TL helped to draft and review
several versions of manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 February 2011 Accepted: 9 June 2011
Published: 9 June 2011
References
1. Domanski MJ, McKinlay S: Successful randomized trials: a handbook for
the 21st century. Philadelphia: Lippincott Williams & Wilkins; 2009.
2. The Cochrane Collaboration:[http://www.cochrane.org], Accessed, February
26, 2011.
3. Clinicaltrials.gov:[http://www.clinicaltrials.gov], Accessed, October 28, 2010.
4. The WHO ICTRP:[http://www.who.int/ictrp/en/], Accessed February 6, 2011.
5. Devasenapathy N, Singh K, Prabhakaran D: Conduct of clinical trials in
developing countries: a perspective. Curr Opin Cardiol 2009, 24(4):295-300.
6. Lang TA, White NJ, Tran HT, Farrar JJ, Day NP, Fitzpatrick R, Angus BJ,
Denis E, Merson L, Cheah PY, Chilengi R, Kimutai R, Marsh K: Clinical
research in resource-limited settings: enhancing research capacity and
working together to make trials less complicated. PLoS Negl Trop Dis
2010, 29(6):e619.
7. Hayasaka E.: Approaches Vary for Clinical Trials in Developing Countries. J
Natl Cancer Inst Monogr 2005, 97(19):1401-1403.
8. Shapiro HT, Meslin EM: Ethical issues in the design and conduct of
clinical trials in developing countries. N Engl J Med 2001, 345(2):139-142.
9. Schuklenk U: For-Profit Clinical Trials in Developing Countries–Those
Troublesome Patient Benefits. Am J Bioeth 2010, 10(6):52-54.
10. Howie S: Conduct of clinical trials in developing countries. Lancet 2007,
18(9587):562, 370.
11. Miran E: Clinical trials in the developing world. Lancet 2007, 369(9576):1859.
12. Beran RG: The ethics of clinical research and the conduct of drug trials:
International comparisons and codes of conduct. Med Law 2000,
19:501-21.
13. Global Health Clinical Trials:[http://ght.globalhealthehub.org/], Accessed
June 9, 2011.
14. Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester R, Mills E, Volmink J,
Yondo D, Essi MJ, Bonono-Momnougoui RC, Mba R, Ndongo JS, Nkoa FC,
Atangana Ondoa H: The Cameroon Mobile Phone SMS (CAMPS) trial: a
protocol for a randomized controlled trial of mobile phone text
messaging versus usual care for improving adherence to highly active
anti-retroviral therapy. Trials 2011, 12(1):5.
15. UNICEF Cameroon statistics:[http://www.unicef.org/infobycountry/
cameroon_statistics.html], Accessed April 11, 2011. .
16. World Health Organization: Yaoundé, Cameroon-HUG, Switzerland. 2010
[http://www.who.int/patientsafety/implementation/apps/first_wave/
cameroon_hug/en/index.html], Accessed April 11, 2011. .
17. Lewis MP: Ethnologue: Languages of the World, Sixteenth edition. Dallas,
Texas: SIL International. 2009 [http://www.ethnologue.com/], Accessed
April 11, 2011. .
18. Antes G: The new CONSORT statement. BMJ 2010, 340:c1432.
Mbuagbaw et al. Trials 2011, 12:145
http://www.trialsjournal.com/content/12/1/145
Page 6 of 7
19. Lorenzo C, Garrafa V, Solbakk JH, Vidal S: Hidden risks associated with
clinical trials in developing countries. J Med Ethics 2010, 36:111-115.
20. Holtedahl Knut, Bonono Leonard, Salpou Daniel: The value of population
campaigns offering free-of-charge HIV-testing: Observational study in a
town in Cameroon. Nor epidemiol 2005, 15:159-164.
21. Shet A, Arumugam K, Rodrigues R, Rajagopalan N, Shubha K, Raj T,
D’Souza G, De Costa A: Designing a mobile phone-based intervention to
promote adherence to antiretroviral therapy in South India. AIDS Behav
2010, 14:716-720.
22. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use: Guideline for Good Clinical
Practice E6 (R1):[http://ichgcp.net/], Accessed December 12, 2010.
23. Grimes DA, Hubacher D, Nanda K, Schulz KF, Moher D, Altman DG: The
Good Clinical Practice guideline: a bronze standard for clinical research.
Lancet 2005, 366(9480):172-174.
24. Lang T, Cheah PY, White NJ, Clinical research: time for globally sensible
guidelines. Lancet 2011, in Press..
25. CRASH-2 trial collaborators: Effects of tranexamic acid on death, vascular
occlusive events, and blood transfusion in trauma patients with
significant haemorrhage (CRASH-2): a randomised, placebo-controlled
trial. Lancet 2010, 376(9734):23-32.
26. WMA: Declaration of Helsinki-Ethical Principles for Medical Research
Involving Human subjects.[http://www.wma.net/en/30publications/
10policies/b3/index.html], Accessed February 6, 2011.
27. The CONSORT Statement:[http://www.consort-statement.org/consort-
statement/], Accessed February 6, 2011.
28. Kilama WL, Chilengi R, Wanga CL: Towards an African-driven malaria
vaccine development program: history and activities of the African
Malaria Network Trust (AMANET). Am J Trop Med Hyg 2007, 77(6):282-288.
29. Greenwood BM, Bhasin A, Bowler CH, Naylor H, Targett GA: Capacity
strengthening in malaria research: the Gates Malaria Partnership. Trends
Parasitol 2006, 22(7):278-284.
30. Kitua AY, Corrah T, Herbst K, Nyirenda T, Agwale S, Makanga M, Mgone CS:
Strengthening capacity, collaboration and quality of clinical research in
Africa: EDCTP Networks of Excellence. Tanzan J Health Res 2009,
11(1):51-54.
31. Shafiq N, Pandhi P, Malhotra S: Investigator-initiated pragmatic trials in
developing countries - much needed but much ignored. Br J Clin
Pharmacol 2009, 67(1):141-2.
32. Kasper CK: Conduct of clinical trials in developing countries. Haemophilia
2002, 8:166-169.
33. Varmus H, Satcher D: Ethical complexities of conducting research in
developing countries. N Engl J Med 1997, 337:1003-5.
doi:10.1186/1745-6215-12-145
Cite this article as: Mbuagbaw et al.: The challenges and opportunities
of conducting a clinical trial in a low resource setting: The case of the
Cameroon mobile phone SMS (CAMPS) trial, an investigator initiated
trial. Trials 2011 12:145.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mbuagbaw et al. Trials 2011, 12:145
http://www.trialsjournal.com/content/12/1/145
Page 7 of 7
